Coherus Biosciences reaffirms 2023 net revenue view in excess of $275M

Consensus $299.2M. For Q2 2023, Coherus expects to report at least $48 – 53 million of net product revenue from sales of UDENYCA and CIMERLI. For the fiscal year 2023, Coherus continues to project net revenues in excess of $275 million, including at least $100 million from net sales of CIMERLI, with the balance comprising net sales of UDENYCA, YUSIMRY and toripalimab. Additionally, Coherus affirms prior guidance for full year 2023 combined R&D and SG&A expenses in the range of $315 to $335 million, including approximately $50 million of stock-based compensation expense and excluding the Surface Oncology acquisition cost as well as any potential collaboration upfront payments to Klinge Pharma for the in-license of its Eylea biosimilar program or milestone payments to Junshi Biosciences due upon U.S. approval of toripalimab.